Analytica recruits clinicians for PeriCoach rollout

Analytica (ASX:ALT) has completed recruitment for a cohort of clinicians to support the controlled launch of PeriCoach, the company’s device therapy for urinary incontinence in women.

Analytica has identified and trained a group of Australian physiotherapists, urologists and specialist women’s health GPs to become its first PeriCoach referral partners, the company announced in a market update.

The clinicians have been provided with a device for their own use, to gain familiarity with the system, and a Wi-Fi enabled tablet preconfigured to facilitate in-clinic purchases.

They can choose to take consignment stock for immediate access by patients or refer patients to the PeriCoach website with a one-off purchasing code.

The tablet also serves to help with demonstrating the system, training patients and providing tools for the clinician to develop treatment regimes.

Analytica is recruiting a clinical sales team to help promote the product in Australia. The company has already appointed a NSW regional account manager, and this will be followed by the recruitment of managers for Queensland, Victoria/Tasmania and SA/WA.

As it awaits approvals for the product in the US and the EU, Analytica is also preparing commercialisation strategies in the US through a dedicated marketing, reimbursement and regulatory team. The company is also searching for a European marketing manager and sales managers.

The specialist manufacturer Analytica has engaged to produce the devices meanwhile commenced production in late May and is incorporating efficiencies in the reliability, speed and volume in throughput based on the experience with the controlled release of PeriCoach to date.

Analytica (ASX:ALT) shares were trading 6.98% lower at $0.04 as of around 1 pm on Thursday.